Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

248 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Real world effectiveness of subcutaneous semaglutide in type 2 diabetes: A retrospective, cohort study (Sema-MiDiab01).
Berra CC, Rossi MC, Mirani M, Ceccarelli Ceccarelli D, Romano C, Sassi L, Peretti E, Favacchio G, Pastore I, Folini L, Graziano G, Lunati ME, Solerte SB, Fiorina P. Berra CC, et al. Among authors: fiorina p. Front Endocrinol (Lausanne). 2023 Jan 18;13:1099451. doi: 10.3389/fendo.2022.1099451. eCollection 2022. Front Endocrinol (Lausanne). 2023. PMID: 36743930 Free PMC article.
Finerenone in Patients With Chronic Kidney Disease and Type 2 Diabetes by Sodium-Glucose Cotransporter 2 Inhibitor Treatment: The FIDELITY Analysis.
Rossing P, Anker SD, Filippatos G, Pitt B, Ruilope LM, Birkenfeld AL, McGill JB, Rosas SE, Joseph A, Gebel M, Roberts L, Scheerer MF, Bakris GL, Agarwal R; FIDELIO-DKD and FIGARO-DKD Investigators. Rossing P, et al. Diabetes Care. 2022 Dec 1;45(12):2991-2998. doi: 10.2337/dc22-0294. Diabetes Care. 2022. PMID: 35972218 Free PMC article. Clinical Trial.
Glucagon-like peptide 1 receptor is a T cell-negative costimulatory molecule.
Ben Nasr M, Usuelli V, Dellepiane S, Seelam AJ, Fiorentino TV, D'Addio F, Fiorina E, Xu C, Xie Y, Balasubramanian HB, Castillo-Leon E, Loreggian L, Maestroni A, Assi E, Loretelli C, Abdelsalam A, El Essawy B, Uccella S, Pastore I, Lunati ME, Sabiu G, Petrazzuolo A, Ducci G, Sacco E, Centofanti L, Venturini M, Mazzucchelli S, Mattinzoli D, Ikehata M, Castellano G, Visner G, Kaifeng L, Lee KM, Wang Z, Corradi D, La Rosa S, Danese S, Yang J, Markmann JF, Zuccotti GV, Abdi R, Folli F, Fiorina P. Ben Nasr M, et al. Among authors: fiorina p. Cell Metab. 2024 Jun 4;36(6):1302-1319.e12. doi: 10.1016/j.cmet.2024.05.001. Cell Metab. 2024. PMID: 38838642
Hyperglycemia impairs EAAT2 glutamate transporter trafficking and glutamate clearance in islets of Langerhans: implications for type 2 diabetes pathogenesis.
Galli A, Moretti S, Dule N, Di Cairano ES, Castagna M, Marciani P, Battaglia C, Bertuzzi F, Pastore I, Fiorina P, La Rosa S, Davalli A, Folli F, Perego C. Galli A, et al. Among authors: fiorina p. Am J Physiol Endocrinol Metab. 2024 May 1. doi: 10.1152/ajpendo.00069.2024. Online ahead of print. Am J Physiol Endocrinol Metab. 2024. PMID: 38690938
TMEM219 regulates the transcription factor expression and proliferation of beta cells.
D'Addio F, Assi E, Maestroni A, Rossi G, Usuelli V, Petrazzuolo A, Nardini M, Loretelli C, Ben Nasr M, Fiorina P. D'Addio F, et al. Among authors: fiorina p. Front Endocrinol (Lausanne). 2024 Jan 22;15:1306127. doi: 10.3389/fendo.2024.1306127. eCollection 2024. Front Endocrinol (Lausanne). 2024. PMID: 38318298 Free PMC article.
Type 2 diabetes mellitus pharmacological remission with dapagliflozin plus oral semaglutide.
Lunati ME, Cimino V, Bernasconi D, Gandolfi A, Morpurgo PS, Tinari C, Lazzaroni E, Baruffaldi L, Muratori M, Montefusco L, Pastore I, Rossi A, Franzetti IG, Muratori F, Manfrini R, Disoteo OE, Terranova R, Desenzani P, Girelli A, Ghelardi R, D'Addio F, Ben Nasr M, Berra C, Folli F, Bucciarelli L, Fiorina P. Lunati ME, et al. Among authors: fiorina p. Pharmacol Res. 2024 Jan;199:107040. doi: 10.1016/j.phrs.2023.107040. Epub 2023 Dec 20. Pharmacol Res. 2024. PMID: 38128857 Free article.
Impact of Finerenone-Induced Albuminuria Reduction on Chronic Kidney Disease Outcomes in Type 2 Diabetes : A Mediation Analysis.
Agarwal R, Tu W, Farjat AE, Farag YMK, Toto R, Kaul S, Lawatscheck R, Rohwedder K, Ruilope LM, Rossing P, Pitt B, Filippatos G, Anker SD, Bakris GL; FIDELIO-DKD and FIGARO-DKD Investigators. Agarwal R, et al. Ann Intern Med. 2023 Dec;176(12):1606-1616. doi: 10.7326/M23-1023. Epub 2023 Dec 5. Ann Intern Med. 2023. PMID: 38048573 Clinical Trial.
Daytime hypoglycemic episodes during the use of an advanced hybrid closed loop system.
Rossi A, Montefusco L, Reseghetti E, Pastore IF, Rossi G, Usuelli V, Loretelli C, Boci D, Ben Nasr M, D'Addio F, Bucciarelli L, Argenti S, Morpurgo P, Lunati ME, Fiorina P. Rossi A, et al. Among authors: fiorina p. Diabetes Res Clin Pract. 2023 Dec;206:111011. doi: 10.1016/j.diabres.2023.111011. Epub 2023 Nov 11. Diabetes Res Clin Pract. 2023. PMID: 37956944
248 results